Virpax Pharmaceuticals, Inc.

Equities

VRPX

US9282512063

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 07/06/2024 BST			5-day change	1st Jan Change
0.7501 ^USD	-6.30%		+7.16%	-76.57%

05-22	Maxim Downgrades Virpax Pharmaceuticals to Hold From Buy	MT
05-15	Virpax Prices Public Offering of Shares, Warrants; Shares Tumble	MT

Virpax Pharmaceuticals, Inc. Appoints Gerald W. Bruce as Executive Vice President, Commercial Operations

September 17, 2019 at 08:36 pm

Virpax® Pharmaceuticals Inc. announced that Gerald W. Bruce, has joined Virpax as Executive Vice President, Commercial Operations. Mr. Bruce most recently served as Vice President of Sales for Specialized Nutrition at Danone North America.

Latest news about Virpax Pharmaceuticals, Inc.

Maxim Downgrades Virpax Pharmaceuticals to Hold From Buy	05-22	MT
Virpax Prices Public Offering of Shares, Warrants; Shares Tumble	05-15	MT
Top Premarket Decliners	05-15	MT
Investors Await Key Inflation Data for April as US Futures Remain Flat in Wednesday's Premarket	05-15	MT
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Virpax Pharmaceuticals, Inc. Announces Resignation of Jeffrey Gudin as Chief Medical Officer and Executive Vice President	05-02	CI
Virpax Pharmaceuticals, Inc. Announces Results of Maximum Tolerated Dose Study for Probudur	04-30	CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	03-15	MT
Virpax Pharmaceuticals Announces Preliminary Results of Probudurtm Pilot Study with the U.S. Army Institute of Surgical Research	02-07	CI
Virpax Pharmaceuticals Stockholders Approve Reverse Stock Split Plan; Shares Fall	12-29	MT
Virpax Pharmaceuticals Announces Leadership Transition	11-17	CI
Virpax Pharmaceuticals, Inc. Announces CEO Changes	11-16	CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-16	CI
Virpax Pharmaceuticals Announces Envelta Remains on Track for Trial in Humans Following FDA Review	31/10/23	CI
Virpax Names Gerald Bruce as CEO of Novvae Pharmaceuticals Unit	02/10/23	MT
Novvae Pharmaceuticals Announces Executive Appointments	02/10/23	CI
Virpax Forms New Unit Novvae Pharmaceuticals	18/09/23	MT
Virpax Pharmaceuticals, Inc Announces the Formation of Novvae? Pharmaceuticals	18/09/23	CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Virpax Pharmaceuticals, Inc. Files Provisional Patent Application for NSAID Formulation and Method	10/08/23	CI
Virpax Pharmaceuticals Files Patent For Envelta Product Candidate	13/07/23	MT
Top Premarket Gainers	28/06/23	MT
Virpax Pharmaceuticals Names New CFO	20/06/23	MT
Virpax Pharmaceuticals, Inc. Announces Executive Changes	20/06/23	CI

Chart Virpax Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and proprietary drug delivery systems across various pain indication. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patientsâ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, AnQlar and NobrXiol. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. The NobrXiol is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy.

Sector

Biotechnology & Medical Research

Calendar

11/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.7501 USD

Average target price

20 USD

Spread / Average Target

+2,566.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VIRPAX PHARMACEUTICALS, INC.	-76.57%	879K
MODERNA, INC.	+51.85%	57.87B
LONZA GROUP AG	+41.42%	40.25B
IQVIA HOLDINGS INC.	-5.25%	39.94B
CELLTRION, INC.	-5.16%	28.54B
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B
BIO-TECHNE CORPORATION	+0.61%	12.23B
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B

Other Biotechnology & Medical Research